Curriculum Vitae

Personal information

First name / Surname **Stefania Chiappini**
Nationality Italian

Date of birth August 17th, 1984

Gender F

Email: stefaniachiappini9@gmail.com

2,281 Citations by 1,751 documents
87 Documents
h-index 30 (August 2025)

Work experience

September 2025
Associate Professor (MED/25) at UniCamillus- - Saint Camillus International University of Health and Medical Sciences, Rome (IT)

June 2024
National Scientific Qualification for Associate Professor (valid from 25th June 2024 to 25th June 2036)

September 2023/ To September 2025
Researcher in Psychiatry (MED/25) at UniCamillus- - Saint Camillus International University of Health and Medical Sciences, Rome (IT)

July 2022/June 2023
Postdoc fellowship
School of Life and Medical Sciences - Allied Health Professions, Dentistry, Nursing and Pharmacy
Department of Clinical, Pharmaceutical and Biological Sciences
University of Hertfordshire, Hatfield, Herts (UK)

May 2019/to date
Psychiatric hospital Villa Maria Pia- Roma (RM), Italy
Psychiatric Consultant
Direct evaluation and treatment for patients with both acute and chronic mental illnesses

- Past studies:

-*Abilify Maintena® in SCHIZOPHRENIC PATIENTS WITH AUD AND SUD* (EU study number: OPEL/2020/007) (January 2021-January 2022)

-*VESPA (Vortioxetine in the Elderly vs SSRIs: a pragmatic assessment) study (*July 2020/October 2022) - Research grant (G. D'Annunzio University -Chieti, Italy)

- Ongoing studies (in collaboration with G. D'Annunzio University -Chieti, Italy):

-*Esketamine (Spravato®)* as therapy of treatment-resistant depression (Prof.Martinotti)
-*DUAL DISORDER RATING SCALE – DDRS* validation – PI: Prof. Martinotti
-*DDT (Dual Disorder Trial):* it investigates the role of Brexpiprazole, Lurasidone, and Quetiapine in Schizophrenic subjects with comorbid alcohol or substance use disorder – PI: Prof. Martinotti
- *Neurobiological correlates of Alcohol Use Disorder after transcranial Direct Current Stimulation (tDCS) treatment* – PI: Prof. Martinotti
-*Clinical and psychopathological characterization and inflammatory/metabolic correlates of depressive episodes (SFIDE) – PI:* Prof. Sani
- *BipOlAR Disorder Integrative stagiNG: incorporating the role of biomarkers into Progression AcrosS Stages (BOARDING-PASS) - PI:* Prof. Dell'Osso
- Evaluation of the effectiveness of family psychoeducational intervention for major depression: a randomised controlled trial' PI: Prof. Fiorillo
- *Retrospective, observational, multicentre study on the relationship between dose (initial dose, dose reached and time to reach target dose), efficacy and tolerability of Vortioxetine treatment (VRTX SLOW)* – PI: Prof. Cuomo
- Studio osservazionale REal-world Multicentric Effectiveness study of Desvenlafaxine in Major Depressive Disorder: A Symptom-focused StudY (REMEDY-MDD) – PI Prof. Martinotti

February 2017/May 2019
Psychiatric hospital Villa Rosa- Viterbo (VT), Italy
Psychiatric Consultant
Direct evaluation and treatment for patients with both acute and chronic mental illnesses

July 2018/ to March 2020
Substitute doctor in the public service at the following departments:
ASL VT/C (CSM Vignanello, CSM Vetralla);
ASL RM 1 (Regina Coeli Home district);
ASL RM 2 (CSM II distretto Via degli Eucalipti; Rebibbia Home district)

March 2017/September 2017
Chief Medical Officer at Therapeutic Community SRSRhh24 Johnny & Mary- Paliano (FR), Italy

July2016/January 2017
Forensic Psychiatric Hospital, Carovigno (BR), Italy
Psychiatric Consultant
Treatment and rehabilitation of persons with mental disorders who committed a criminal offence but lack criminal responsibility due to mental illness and deemed as socially dangerous

July 2011/22nd June 2016
Residency
Gemelli General Hospital – Department of Addictions and Psychiatry – Rome (RM), Italy
Areas of Special Expertise: Addictions, Drug Dependence, Mood Disorders and Personality Disorders, Psychopharmacology, Clinical psychiatric diagnosis and treatment, and, in details, clinical expertise in evaluation of the entire range of psychiatrically ill patients and competence in psychiatric treatment, using the fundamental modalities of therapy currently available; in addition, the evaluation, treatment, research, and teaching of substance-related disorders. Treatment of patients with dual diagnosis, specifically those with substance-related and comorbid psychiatric disorders. Interpersonal communication skills with patients, their families and others caring for the patient.
Past Research:
-Observational cohort study to evaluate the safety of Agomelatine in standard medical practice on depressed patients.
-Alterations of BDNF in gamblers.
-Phase III, multicenter, open-label study to evaluate the efficacy and the safety of Dimatex (Lofexidine) in the treatment of withdrawal symptoms in patients in detoxification from opioids.

March 2016/June 2016
Psychiatry resident
Psychiatric acute care unit, Santo Spirito Hospital, Rome (RM), Italy.

This unit stabilizes and treats adults experiencing mental health crises, such as those who are suicidal, homicidal or psychotic

July 2014/June 2016
Medical Ward service
Neuropsychiatric hospital San Valentino- Rome (RM), italy

April 2013/November 2013
Academic visiting researcher
International Centre for Drug Policy (ICDP), St George's University of London
National Programme on Substance Abuse Deaths (np-SAD): Data entry, analyses (IBM SPSS use and descriptive statistics) and assistance with report writing (*Drug-related deaths in the UK Annual Report 2013*).
Preparation of specialist reports on Methoxetamine and Mephedrone.
Coordinator: Prof. Schifano

Teaching activities

November 2023/to date
Mentor assignment for Residents in Psychiatry – G. D'Annunzio University, Chieti, Italy

November 2023/to date
Lecturer in Psychiatry SSD MED/25 n. 10 hours for the Degree Course in Dentistry - IV year at UniCamillus University, Rome, Italy

March 2023/ to date
Teaching activity on the subject of "Psychiatry" in the School of Specialisation in Short Psychotherapy with a Strategic Approach, Institute for the Study of Psychotherapy (ISP), Rome, Italy

N**ovember 2022/to date**
Lecturer in Psychiatry SSD MED/25 n. 30 hours for the Degree Course in Medicine- IV year at UniCamillus University, Rome, Italy

November 2022/to date
Lecturer in Psychiatry SSD MED/25 n. 14 hours for the Degree Course in Nursing-III year at UniCamillus University, Rome, Italy

November 2022/to date
Lecturer in Psychiatry SSD MED/25 n. 10 hours for the Degree Course in Physiotherapy- 2nd year at UniCamillus University, Rome, Italy

December 2019-to date
Lecturer in the Master degree on Addiction – Institute for the Study of Psychotherapies (ISP), Rome, Italy

November 2019-to February 2023
Lecturer in the Physiotherapy degree course – Catholic University of the Sacred Heart – Villa Immacolata, S. Martino al Cimino (VT), Italy

October 2018/November 2018
Lecturer in the First Level Degree Course of Psychiatric Rehabilitation, Sapienza University- Viterbo (VT), Italy

Education and training

Selected for the Training Masterclass on 'Obsessive Compulsive Spectrum Disorder: from translational models to clinical management'
ECNP - 19 to 23 June 2024

Teaching Methodology Academy – UniCamillus -Rome, Italy

December 2017/ July 2022
PhD in Pharmacy, Pharmacology and Postgraduate Medicine
School of Life and Medical Sciences - Allied Health Professions, Dentistry, Nursing and Pharmacy
Department of Clinical, Pharmaceutical and Biological Sciences
University of Hertfordshire, Hatfield, Herts (UK)

Final thesis: Assessing the extent and characteristics of non-medical use of a range of prescribed drugs: epidemiological and pharmacovigilance approaches

July 2021
ATOMIC-ADDICTION TO MEDICATION: IMPROVING CARE. Non-medical use of prescription drugs.
Available online: https://addiction-to-medication.org/atomic/

June 2021
Pharmacovigilance Training -Modules: Drug Safety, Global Regulatory Requirements Pharmacovigilance, Signalling and Risk Assessment. Available on line: https://www.whitehalltraining.com/all-pharmacovigilance-courses

April 2021
Good Clinical Pharmacovigilance Practice Training.
Available online: https://www.pharmalessons.com/trainingcampus/course/view.php?id=10

April 2021
MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA). E-learning module on Adverse Drug Reactions (ADRs). 'Adverse Drug Reactions: reporting makes medicines safer'.
Available online: https://yellowcard.mhra.gov.uk/resources/story_html5.html?lms=1

July 2020
Uppsala Monitoring Centre
Online course: Introduction to pharmacovigilance
Online course: Signal detection and causality assessment
Online course: Statistical reasoning and algorithms in pharmacovigilance

January2017-January 2018
II level **Master University Degree** in Forensic Psychology and Criminology
LUMSA University, Rome- Italy
Dissertation thesis on: IL PAZIENTE PSICHIATRICO AUTORE DI REATO NELLA TRANSIZIONE DAGLI OPG ALLE REMS. CONSIDERAZIONI E PROSPETTIVE.
Mark: 110/110 cum laude

1st July 2011/ 22nd June 2016
Residency
School in Psychiatry and Clinical Psychology
Gemelli General Hospital, Catholic University – Rome (RM), Italy
Thesis in: Misuse of pregabalin and gabapentin in the last decade: analysis and assessment of Adverse Drug Reactions (ADR) reported to the European Medicines Agency (EMA) (in collaboration with Prof. Schifano, University of Hertfordshire School of Life and Medical Sciences; Hatfield, Herts-UK)
Mark: 50/50 cum laude

May-June 2016
Mindfulness Based Stress Reduction training
De Santis Clinical Center, Rome (RM), Italy

8th-9th of May 2015
Training on Good Clinical Practice (GCP) in clinical trials (First level)
Gemelli General Hospital, Catholic University – Rome (RM), Italy

January 2014/ June 2014
The Italian School on Addiction
Council of Ministers- Italian Department for Anti-Drug Policies (DPA)– Rome, Italy
Final project: Dysregulation of reward and dopaminergic transmission in Pathological Gambling: an experimental study using the technic 123I-FP-CIT SPECT

October 2011/ September 2012
Course of Phenomenological Psychopathology (first level)– Florence, Italy

February 2011 **MEDICAL LICENSURE** (mark: 270/270)

August 2010
Department of Neurology - University Medical Centre Ljubljana - Slovenia
Professional Exchange- International Federation of Medical Students Association

Diagnosis and treatment of cognitive disorders, autonomic nervous system disorder, movement disorder; stroke unit

October 2004/July 2010
Degree in Medicine and Surgery - Catholic University of the Sacred Heart, Rome (RM), Italy
Thesis in Psychiatry: Psychopathologic aspects of obesity: psychodiagnostic evaluations of bariatric surgery applicants
(Final mark: 110/110 cum laude)

September 2006/July 2007
Erasmus Program
Facultad de Medicina y Cirugía - Universidad De Salamanca – Salamanca, Spain

September 1998 / July 2003
'Benedetto Marzolla' Classical high school– Brindisi (BR), Italy
(Final mark: 100/100)

PERSONAL SKILLS

BLS-D COURSE (December 04th 2023).

Mother tongue: Italian

Other languages

	COMPREHENSION*		SPEAKING*		WRITING*
	LISTENING	READING	ORAL INTERACTION	ORAL PRODUCTION	
English	C1	C1	B2	B2	C1
Spanish	C1	C1	C1	C1	C1
French	B2	B2	B2	B2	B2

(*)Common European Framework of Reference for Languages

Course of Scientific English- October 2024
UniCamillus – Rome, Italy

September 2017
IELTS Certification: average band 6.5

July 2015/ October 2015
Course of English, level B2
Scuola Internazionale di Lingue
Via Venti Settembre – Rome, Italy

October 2010
TOEFL test
Mark: 80

August 2004
University of Malta
English course – Level: Upper Intermediate

November 2006
BULATS (ALTE) - Spanish
Level C1/4

October 2006
Universidad de Salamanca
Spanish Course – Diploma Superior de Espanol

Other certifications

April 2021
R101 An Introduction to **R** (Electv training)
R102 An Introduction to **R** (Electv training)
R103 An Introduction to **R** (Electv training)

December 2003
ECDL (European Computer Driving Licence)
Base Concepts, File Management, Microsoft Word, Microsoft Excel, Microsoft Access, Microsoft Power Point, Microsoft Internet Explorer 5, Microsoft Outlook Express 5

Additional information

November 2020
Winner of the Post Graduate Researcher conference funding grant – University of Hertfordshire - UK

October 2020
Member of the Italian Society of Addiction Diseases (Società Italiana Patologie da Dipendenza-S.I.Pa.D.)

October 2020
Member of the International Society of Substance Use Professionals (ISSUP).

October 2020
Member of the Network of Early Career Professionals working in the area of Addiction Medicine (NECPAM)

October 2020
Member of the Young Psychiatrists' Network (YPN)

February 2015
Travel Grant (supported by Lilly) at the 17th Congress of the European Society for Sexual Medicine (Copenhagen) for the abstract: *Hyper sexuality and compulsive behaviors triggered by dopaminergic therapies in a case of Parkinson's Disease*

April 2011
Prize-Scholarship "Studenti Meritevoli Regione Abruzzo" - Banca di Lanciano e Sulmona - Italy

December 2004
Prize-Scholarship "Alfieri del Lavoro" - Federazione Nazionale dei Cavalieri del Lavoro- Italy

August 2004
Prize-Scholarship by Italian Foreign Affairs Ministry (English course in the University of Malta)

Annexes

Publications on *peer-reviewed* journals

Exploring Dual Diagnoses: Psychopathological Characteristics in the Co-Occurrence of Schizophrenia and Addiction: A scoping review
Psychopathology, in press

Anomalous self-experience in schizophrenia spectrum disorders: Phenomenological and psychopathological correlates.
Mosca A, **Chiappini** S, Pasino A, Miuli A, Marrangone C, Pettorruso M, Martinotti G.
Schizophrenia Research: Cognition (42) 100389 https://doi.org/10.1016/j.scog.2025.100389

Exploring emerging psychopathological characteristics and challenges of novel depression subtypes: insights from the literature.
Chiappini S, Sampogna G, Ventriglio A, Menculini G, Ricci V, Pettorruso M, Volpe U, Martinotti G.
Front Psychiatry. 2025 Jul 2;16:1613251. doi: 10.3389/fpsyt.2025.1613251. PMID: 40673231; PMCID: PMC12263598.

Navigating the challenges of substance use and psychopathology in depression, bipolar disorder, and schizophrenia.
Chiappini S, Mosca A, Semeraro F, Amerio A, Berardelli I, Cremaschi L, Di Bernardo I, Pettorruso M, Serafini G, Dell'Osso B, Martinotti G. Compr Psychiatry. 2025 Jul 8;142:152616. doi: 10.1016/j.comppsych.2025.152616. Epub ahead of print. PMID: 40652744.

Bartoli, F., Cavaleri, D., Riboldi, I. et al. Efficacy and Tolerability of Vortioxetine Versus Selective Serotonin Reuptake Inhibitors for Late-Life Depression: A Post-hoc Analysis of the VESPA Study. Drugs Aging (2025).
https://doi.org/10.1007/s40266-025-01231-3

Clinical Insights and Strategies to Managing Depression Subtypes Associated with Tobacco dependence: A Response to the Letter to the Editor.
Chiappini S, Sampogna G, Ventriglio A, Menculini G, Ricci V, Pettorruso M, Volpe U, Martinotti G. Expert Rev Neurother. 2025 May 14:1-2. doi: 10.1080/14737175.2025.2506463. Epub ahead of print. PMID: 40357980.

Alcohol vs. Cocaine: Impulsivity and Alexithymia in Substance Use Disorder.
Mosca, A., Bubbico, G., Cavallotto, C., **Chiappini**, S., Allegretti, R., Miuli, A., Marrangone, C., Ciraselli, N., Pettorruso, M., & Martinotti, G. (2025).
Behavioral Sciences, 15(6), 711. https://doi.org/ 10.3390/bs15060711

Adverse Drug Reactions Associated with Concomitant Use of Calcium Channel Blockers and Cocaine: An Analysis of FDA Adverse Events Reporting System Data
Chiappini S, Mosca A, Papanti Pelletier GD, Corkery JM, Guirguis A, Arillotta D, Martinotti G, Schifano F.
Journal of Clinical Medicine, 2025; 14(10):3461. https://doi.org/10.3390/jcm14103461

Cannabis use and psychotic-like experiences: A systematic review of biological vulnerability, potency effects, and clinical trajectories
Ricci V, **Chiappini** S, Martinotti G, Maina G.
Psychiatry Research, volume 348, June 2025, 116496

Advancing Knowledge at the Intersection of Neuropsychopharmacology and Addiction.
Martinotti, G., & **Chiappini, S.**
Clinical Neuropsychopharmacology and Addiction. 2025. doi: Retrieved fr Martinotti om https://www.sciltp.com/journals/cna/article/view/790

Emerging strategies and clinical recommendations for the management of novel depression subtypes.
Stefania Chiappini, Gaia Sampogna, Antonio Ventriglio, Giulia Menculini, Valerio Ricci, Mauro Pettorruso, Umberto Volpe & Giovanni Martinotti
Expert Review of Neurotherapeutics, DOI: 10.1080/14737175.2025.2470973

Over-the-counter Psychosis: A Systematic Review of the Misuse of Antihistamines, Cough Medicines, and Decongestants and the Risk of Developing Psychosis.
Mosca A, **Chiappini** S, Mancusi G, Miuli A, Marrangone C, Allegretti R, Panichella S, Cavallotto C, Corkery JM, Pettorruso M, Martinotti G, Schifano F.
Curr Neuropharmacol. 2025 Feb 18. Doi: 10.2174/011570159X344365250114064248. Epub ahead of print. PMID: 39976040.

Alcohol Use Disorders and Suicidal Behaviour: A Narrative Review.
Lupi M, **Chiappini** S, et al.
Actas Españolas De Psiquiatría, vol. 53, no. 1, Jan. 2025, pp. 165-80, doi:10.62641/aep.v53i1.1772.

Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective
Chiappini S, Guirguis A, Schifano N, Corkery J, Semeraro F, Mosca A, D'Andrea G, Papanti GD, Arillotta D, Floresta G, Martinotti G, Schifano F.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. Available online 6 December 2024, 111213.
https://doi.org/10.1016/j.pnpbp.2024.111213

Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic review
Chiappini S, Gramuglia PD, Mosca A, Cavallotto C, Miuli A, Corkery JM, Guirguis A, Schifano F, Martinotti G.
Front. Psychiatry 2024, (15). doi: 10.3389/fpsyt.2024.1508732

Substance use, club drugs and psychiatric consequences: a case series
Montemitro C, Mosca A, **Chiappini S**, Miuli A, Schifano A, Gordillo Montano MJ, Merino del Villar C, Allegretti R, Di Petta G, De Berardis D, Pettorruso M, Martinotti G.
Pharmaceuticals. 2024; 17(10):1387. https://doi.org/10.3390/ph17101387

Piperazine abuse and psychosis: a systematic review of the literature
Mosca A, **Chiappini S**, Miuli A, Mancusi G, Cavallotto C, Corkery JM, Miotti L, Pettorruso M, Martinotti G, Schifano F.
Psychiatry International. 2024; 5(3):552-563. https://doi.org/10.3390/psychiatryint5030040

Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-occurring Sub-stance Use Disorder: A Prospective, Multicentric, Real-World Study
Chiappini S, Cavallotto C, Mosca A, Di Carlo F, Piro T, Giovannetti G, Pasino A, Vicinelli MC, Lorenzini C, Di Paolo M, Pepe M, Di Nicola N, Ricci V, Pettorruso M, Martinotti G
Pharmaceuticals, 2024

New trends of drug abuse in custodial settings: A systematic review on the misuse of over-the-counter drugs, prescription-only-medications, and new psychoactive substances.
Chiappini S, Vaccaro G, Mosca A, Miuli A, Stigliano G, Stefanelli G, Giovannetti G, Carullo R, d'Andrea G, Di Carlo F, Cavallotto C, Pettorruso M, Di Petta G, Corkery JM, Guirguis A, Stair JL, Martinotti G, Fazel S, Schifano F.
Neurosci Biobehav Rev. 2024 Jul;162:105691. doi: 10.1016/j.neubiorev.2024.105691.

Examining Lurasidone Efficacy in Patients with Schizophrenia Spectrum Illness and Concurrent Alcohol and Substance Use Disorder: A Prospective, Multicentric, Real-World Investigation.
Cavallotto C, **Chiappini S**, Mosca A, d'Andrea G, Di Carlo F, Piro T, Susini O, Stefanelli G, Di Cesare A, Ricci V, et al.
Journal of Clinical Medicine. 2024; 13(8):2206. https://doi.org/10.3390/jcm13082206

The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world.
d'Andrea G, Pettorruso M, Di Lorenzo G, Rhee TG, **Chiappini S,** Carullo R, Barlati S, Zanardi R, Rosso G, Di Nicola M, Andriola I, Marcatili M, Clerici M, Dell'Osso BM, Sensi SL, Mansur RB, Rosenblat J, Martinotti G, McIntyre RS.
Journal of Affective Disorder 2024.

Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel.
Maina G, Adami M, Ascione G, Bondi E, De Berardis D, Delmonte D, Maffezzoli S, Martinotti G, Nivoli A, Ottavianelli E, Delphi Panel Collaboration Group, (Tiziano Acciavatti, Umberto Albert, Sara Andreoli, Ileana Andriola, Fausto Antonielli Romanini, Roberta Bassetti, Francesca Bettini, Graziella Boi, Paolo Cacciani, Paola Calò, Alessandro Carano, Ilaria Casolaro**,** **Stefania Chiappini**, Paola Clemente, Virginia D'Ambrosio, Giacomo d'Andrea, Tiziana Dario, Pasquale De Fazio, Renato de Filippis, Francesco Di Carlo, Marco Di Nicola, Luca Di Paolo, Giampaolo Di Piazza, Gabriele Di Salvo, Monica Fiori, Alessandro Gentile, Matteo Lupi, Mirko Manchia, Matteo Marcatili, Livio Marchiaro, Vassilis Martiadis, Giulia Menculini, Giovanni Migliarese, Gaetano Nappi, Domenica Nucifora, Miriam Olivola, Claudia Palumbo, Elena Paschetta, Ettore Pasculli, Enrico Pessina, Federica Pinna, Marianna Pinto, Davide Piu, Donato Gerolamo Posadinu, Fabiola Rafone, Valerio Ricci, Ilario Ritacco, Gianluca Rosso, Elisa Simonini, Antonio Ventriglio) & Fagiolini A. (2023).
Annals of general psychiatry, 22(1), 48, https://doi.org/10.1186/s12991-023-00478-7

3-Methoxy-Phencyclidine Induced Psychotic Disorder: A Literature Review and an 18F-FDG PET/CT Case Report. Pharmaceuticals 2024, 17, 452. https://doi.org/10.3390/ph17040452
Pepe, M.; Di Nicola, M.; Cocciolillo, F.; **Chiappini, S**.; Martinotti, G.; Calcagni, M.L.; Sani, G.

Tolerability of vortioxetine compared to selective serotonin reuptake inhibitors in older adults with major depressive disorder (VESPA): a randomised, assessor-blinded and statistician-blinded, multicentre, superiority trial. Ostuzzi G, Gastaldon C, Tettamanti M, Cartabia M, Monti I, Aguglia A, Aguglia E, Bartoli F, Callegari C, Canozzi A, Carbone EA, Carrà G, Caruso R, Cavallotto S, **Chiappini** S, Colasante F, Compri B, D'Agostino A, de Fazio P, de Filippis R, Gari M, Ielmin M, Ingrosso G, Mammarella S, Martinotti G, Rodolico A, Roncone R, Sterzi E, Tarsitani L,Tiberto E, Todini L, Amaddeo F, D'Avanzo B, the VESPA Study Group, Barbato A, Barbui C. E-clinical medicine 2024. https://doi.org/10.1016/j.eclinm.2024.102491

The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world.
D'Andrea G, Pettorruso M, Di Lorenzo G, Rhee TG, **Chiappini S,** Carullo R, Barlati S, Zanardi R, Rosso G, Di Nicola M, Andriola I, Marcatili M, Clerici M, Dell'Osso BM, Sensi SL, Mansur RB, Rosenblat J, Martinotti G, McIntyre RS. Journal of Affective Disorder 2024.

Editorial: Misuse and Abuse of Prescription Drugs in Custodial Settings.
Pirani F, **Chiappini** S, Schifano F, Giorgetti A.
Frontiers in Psychiatry 2023

Exploring the nexus of binge eating disorder (BED), New Psychoactive Substances (NPS), and misuse of pharmaceuticals: charting a path forward.
Chiappini S, Papanti Pelletier DG, Vickers-Smith R, Corkery JM, Guirguis A, Martinotti G, Schifano F.
Expert Opinion on Pharmacotherapy, DOI: 10.1080/14656566.2023.2271389

High-Risk Gaming Is Associated with Frequent Substance Use: An Exploratory Survey among Young Adults.
Di Carlo F, Verrastro V, Alessi MC, Sociali A, Altomare AI, Di Natale C, Stigliano G, Miuli A, Lalli A, Di Petta G, **Chiappini S,** Pettorruso M, Bowden-Jones H, Griffiths MD, Martinotti G.
Eur Addict Res. 2023;29(4):241-252. doi: 10.1159/000529544.

To bridge or not to bridge: Moral Judgement in Cocaine Use Disorders, a case-control study on human morality.
Mosca A, Miuli A, Mancusi G, **Chiappini** S, Stigliano G, De Pasquale A, Di Petta G, Bubbico G, Pasino A, Pettorruso M, Martinotti G.
Social Neuroscience, 2023. https://doi.org/10.1080/17470919.2023.224209

An Update on Psychoactive Substances: Pharmacology and Toxicology Issues.
Chiappini S, Schifano F.
Pharmaceuticals. 2023; 16(8):1177. https://doi.org/10.3390/ph16081177

Predicting outcome with Intranasal Esketamine treatment: a machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).
Pettorruso M, Guidotti R, d'Andrea G, De Risio L, D'Andrea A, **Chiappini** S, Carullo R, Barlati S, Zanardi R, Rosso G, De Filippis S, Di Nicola M, Andriola I, Marcatili M, Nicolò G, Martiadis V, Bassetti R, Nucifora D, De Fazio P, Rosenblat JD, Clerici M, Dell'Osso BM, Vita A, Marzetti L, Sensi SL, Di Lorenzo G, McIntyre RS, Martinotti G.
Psychiatry Research, available online 28 July 2023, 115378. doi:10.1016/j.psychres.2023.115378.

Efficacy of psychosocial and psychological interventions in addition to drug therapy to improve global functioning of inpatients with schizophrenic spectrum and mood disorders: a real-world observational study.
Chiappini S, Di Carlo F, Mosca A, d'Andrea G, Di Paolo M, Lorenzini C, Lupica MG, Sampogna G, Pettorruso M, Fiorillo A, Martinotti G.
Neuropsychiatr Dis Treat. 2023 Aug 30;19:1887-1897. doi: 10.2147/NDT.S418627

Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.
d'Andrea G, **Chiappini** S, McIntyre RS, Stefanelli G, Carullo R, Andriola I, Zanardi R, Martiadis V, Sensi SL, Sani G, Clerici M, Di Lorenzo G, Vita A, Pettorruso M, Martinotti G.
Am J Geriatr Psychiatry. 2023 Jul 8;S1064-7481(23)00351-2. doi: 10.1016/j.jagp.2023.06.016.

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.
Chiappini S, Vickers-Smith R, Harris D, Papanti Pelletier GD, Corkery JM, Guirguis A, Martinotti G, Sensi SL, Schifano F.
Pharmaceuticals 2023, 16, 994. https://doi.org/10.3390/ph16070994

Aripiprazole once monthly as a maintenance treatment for patients with schizophrenia and alcohol/substance use disorder: an observational, real-world study.
Chiappini S, Mosca A, Miuli A, Di Carlo F, d'Andrea G, Napolitano A, Santangelo M, Esposito C, Rosazza A, Haefele E, Di Petta G, Pettorruso M, Sensi SL, Martinotti G.
Advances in Dual Diagnosis 2023 Vol. ahead-of-print No. ahead-of-print. doi: 10.1108/ADD-12-2022-0032.

Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study
Chiappini S, d'Andrea G, De Filippis S, Di Nicola M, Andriola I, Bassetti R, Barlati S, Pettorruso M, Clerici M, Dell'Osso B, Vita A, Martinotti G.
Eur Neuropsychopharmacol. 2023 May 4;74:15-21. doi: 10.1016/j.euroneuro.2023.04.011.

Treating Bipolar Depression with Esketamine: safety and effectiveness in bipolar versus unipolar treatment-resistant depression
Martinotti G, Dell'Osso B, Di Lorenzo G, Maina G, Bertolino A, Clerici M, Barlati S, Rosso G, Di Nicola M, Marcatili M, d'Andrea G*, Cavallotto C, **Chiappini** S, De Filippis S, Nicolò G, De Fazio P, Andriola I, Zanardi R, Nucifora D, Di Mauro S, Bassetti R, Pettorruso M, McIntyre RS, Sensi SL, di Giannantonio M, Vita A, and the REAL-ESK Study Group
Bipolar Disord. 2023 Jan 13. doi: 10.1111/bdi.13296.

Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study).
Martinotti G, Vita A, Fagiolini A, Maina G, Bertolino A, Dell'Osso B, Siracusano A, Clerici M, Bellomo A, Sani G, d'Andrea G, Delle Chiaie R, Conca A, Barlati S, Di Lorenzo G, De Fazio P, De Filippis S, Nicolo` G, Rosso G, Valchera A, Nucifora D, Di Mauro S, Bassetti R, Martiadis V, Olivola M, Belletti S, Andriola I, Di Nicola M, Pettorruso M, McIntyre RS, di Giannantonio M, the REAL-ESK Study Group REAL-ESK [Baldacci G (Department of Mental Health and Addiction Services, Niguarda Hospital, Milan and Department of Mental Health and Addiction Services, Spedali Civili Hospital, Brescia, Italy), Benatti B (Department of Biomedical and Clinical Sciences Luigi Sacco University of Milan, Italy), Simone Bolognesi (University of Siena, Italy), Bufi I (Universita ` degli Studi di Bari "Aldo Moro", Italy), Carullo R (Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy), **Chiappini** S (Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy), Collevecchio R (Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy), Colmegna F (Dipartimento di Salute Mentale e Dipendenze ASST Monza, Italy), de Berardis D (Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy), di Carlo F (Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G.

D'Annunzio, Chieti, Italy), di Natale C (Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy), Giorgelli V (Universita ` degli Studi di Bari "Aldo Moro", Italy), Arianna Goracci (University of Siena, Italy), Lombardozzi G (Neuropsychiatric Clinic, Villa Von Siebenthal, Rome, Italy), Marcatili M (Dipartimento di Salute Mentale e Dipendenze ASST Monza, Italy), Chiara Mattei (Psychiatric Service of the Health District of Bozen, Italy), Mosca A (Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy), Niolu C (University of Rome Tor Vergata, Italy), Percudani M (Department of Mental Health and Addiction Services, Niguarda Hospital, Milan, Italy), Pepe M (Università Cattolica del Sacro Cuore, Rome, Italy), Rossi E (Neuropsychiatric Clinic, Villa Von Siebenthal, Rome, Italy), Scardigli MI (Department of Mental Health and Addiction, ASL Roma5, Rome, Italy), Tatì F (MDSMA Taormina-Messina Sud ASP di Messina, Italy), Vigano C (Department of Biomedical and Clinical Sciences Luigi Sacco University of Milan, Italy), Ventriglio A (Department of Clinical and Experimental Medicine, University of Foggia, Italy), Vismara M (Department of Biomedical and Clinical Sciences Luigi Sacco University of Milan, Italy)].
J Affect Disord. 2022 Dec 15;319:646-654. doi: 10.1016/j.jad.2022.09.043

Editorial: [Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction-Volume II]
Chiappini S, Schifano F, Martinotti G.
Frontiers in Psychiatry 2022. doi: 10.3389/fpsyt.2022.1053896

Evaluating craving in Alcohol Use Disorder: psychometric characteristics of the Craving Typology Questionnaire-15 (CTQ-15).
Martinotti G, Festa G, Ceci F, Callea A, Capparelli A, Bonifaci L, Chillemi E, Pettorruso M, **Chiappini** S, Di Nicola M, Janiri L.
Alcohol Alcohol. 2023 Mar 10;58(2):142-150. doi: 10.1093/alcalc/agac051.

Ibogaine/Noribogaine in the treatment of Substance Use Disorders: a systematic review and Meta-analysis of side effects
Mosca A, **Chiappini** S, Miuli A, Mancusi G, Santovito MC, Di Carlo F, Pettorruso M, Corkery JM, Canessa C, Martinotti G, Di Giannantonio M
Curr Neuropharmacol. 2022 Oct 17. doi: 10.2174/1570159X21666221017085612

Recreational drug misuse and its potential contribution to male fertility levels' decline: a narrative review
Schifano N*, **Chiappini** S*, Mosca A, Miuli A, Santovito MC, Martinotti G, Pettorruso M, Salonia A, Di Giannantonio M, Schifano F
*These authors contributed equally to this work
Brain Sci. 2022, 12(11), 1582; https://doi.org/10.3390/brainsci12111582

Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
Salonia A, Capogrosso P, Boeri L, **Chiappini** S, Schifano N, Cakir O, Rewhorn M, Castiglione F, Alnajjar H, Muneer A, Dehò F, Schifano F, Montorsi F, Fallara G, Harvey H.
Int J Impot Res. 2022 May 5. doi: 10.1038/s41443-022-00568-2.

Pharmacovigilance signals of the opioid epidemic over 10 years: an analysis of pharmacovigilance datasets collecting Adverse Drug Reactions (ADRs) reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)
Chiappini S, Vickers-Smith R, Guirguis A, Corkery JM, Martinotti G, Schifano F.
Pharmaceuticals (Basel). 2022 May 27;15(6):675. doi: 10.3390/ph15060675.

Climate change, biodiversity loss and mental health: A global perspective.
Cianconi P, Hirsch D, **Chiappini** S, Martinotti G, Janiri L.
BJPsych International, 1-4. doi:10.1192/bji.2022.20

Knowledge and use of over-the-counter drugs in Italy: a survey-based study in the general population
Chiappini S, Ceci F, Mosca A, Di Carlo F, Burkauskas J, Pettorruso M, Martinotti G, Guirguis A, Corkery JM; Scherbaum N, Schifano F, Di Giannantonio M.
Curr Neuropharmacol. 2023;21(1):133-141. doi: 10.2174/1570159X20666220714104231.

Misuse of anticholinergic medications: a systematic review.

Chiappini S, Mosca A, Miuli A, Semeraro F, Mancusi G, Santovito MC, Di Carlo F, Pettorruso M, Guirguis A, Corkery JM; Martinotti G, Schifano F, Di Giannantonio M.
Biomedicines. 2022 Feb 1;10(2):355. doi: 10.3390/biomedicines10020355.

Alprazolam-related deaths in Scotland, 2004-2020
Corkery J, Guirguis A, **Chiappini** S, Martinotti G, Schifano F.
J Psychopharmacol. 2022 Sep;36(9):1020-1035. doi: 10.1177/02698811221104065.

Atypical antipsychotic drugs in dual disorders: current evidence and clinical guidelines.
Martinotti G, **Chiappini** S, Mosca A, Miuli A, Santovito MC, Pettorruso M, Skryabin V, Sensi SL, Di Giannantonio M. Current Pharmaceutical Design 2022;28(27):2241-2259.

A focus on abuse/misuse and withdrawal issues with selective serotonin reuptake inhibitors (SSRIS): Analysis of both the European EMA and the US FAERS pharmacovigilance databases.
Chiappini S, Vickers-Smith R, Guirguis A, Corkery JM, Martinotti G, Schifano F.
Pharmaceuticals (Basel). 2022 May 1;15(5):565. doi: 10.3390/ph15050565.

Duration of Untreated Disorder and Cannabis Use: an observational study on a cohort of young Italian patients experiencing psychotic experiences and dissociative symptoms
Ricci V, Martinotti G, Ceci F, **Chiappini** S, Di Carlo F, Burkauskas J, Susini O, Luciani D, Quattrone D, De Berardis D, Pettorruso M, Maina G, Di Giannantonio M.
Int J Environ Res Public Health. 2021 Nov 30;18(23):12632. doi: 10.3390/ijerph182312632

Efficacy of Non-Invasive Brain Stimulation on Borderline Personality Disorder core symptoms: a systematic review. **Chiappini** S, Picutti E, Alessi MC, Di Carlo F, D'Andrea G, Miuli A, Pettorruso M, Martinotti G, Di Giannantonio M.
J Pers Disord. 2022 Oct;36(5):505-526. doi: 10.1521/pedi.2022.36.5.505.

Medications mostly associated with priapism events: assessment of the 2015-2020 Food And Drug Administration (FDA) pharmacovigilance database entries
Schifano N, Capogrosso P, Boeri L, **Chiappini** S, Pozziv E, Belladelli F, Onur Cakir O, Rewhorn M, Castiglione F, Alnajjar HM, Muneer A, Deho' F, Schifano F, Montorsi F, Salonia A.
Journal of Urology, 2021, 206(3): e535.

Drugs associated the most with male-factor infertility: assessment of the 2010-2020 Food And Drug Administration (FDA) pharmacovigilance database
Schifano N, Capogrosso P, Boeri L, **Chiappini** S, Pozziv E, Belladelli F, Onur Cakir O, Rewhorn M, Castiglione F, Alnajjar HM, Muneer A, Deho' F, Schifano F, Montorsi F, Salonia A.
Journal of Urology, 2021, 206(3): e529.

Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature
Martinotti G, **Chiappini** S, Pettorruso M, Mosca A, Miuli A, Di Carlo F, D'Andrea G, Collevecchio R, Di Muzio I, Sensi SL, Di Giannantonio M.
Brain Sciences, 2021 Jun 27;11(7):856. doi: 10.3390/brainsci11070856.

Club drugs and psychiatric sequelae: an issue of vulnerability and previous psychiatric history
Martinotti G, Merino del Villar C, Garcia Cordoba A, Tubau LA, Castro Sánchez L, Di Carlo F, **Chiappini** S, Pettorruso M, Schifano F, Di Giannantonio M.
Int J Environ Res Public Health 2021, 18, 6944. doi:10.3390/ijerph1813694.

New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature
Chiappini S, Mosca A, Miuli A, Santovito MC, Orsolini L, Corkery JM, Guirguis A, Pettorruso M, Di Giannantonio M, Martinotti G, Schifano F.
Medicina 2021, 57(6), 580; doi:10.3390/medicina57060580 .

Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants.
Schifano F, **Chiappini** S, Miuli A, Mosca A, Santovito MC, Corkery JM, Guirguis A, Pettorruso M, Di Giannantonio M, Martinotti G
Front. Psychiatry 2021; 12:657397. doi: 10.3389/fpsyt.2021.657397.

Editorial: Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction.
Chiappini S, Schifano F, Martinotti G.
Front. Psychiatry 2021;12:688434. doi: 10.3389/fpsyt.2021.688434.

The e-psychonaut drugs' psychopharmacology.
Schifano F, **Chiappini** S, Corkery JM, Guirguis A, Scherbaum N.
Curr Opin Pharmacology, 2021, 57: 165-174. Doi: 10.1016/j.coph.2021.02.008.

New Psychoactive Substances (NPS) and Serotonin Syndrome onset: a Systematic Review.
Schifano, **Chiappini** S, Miuli A, Corkery JM, Scherbaum N, Napoletano F, Arillotta D, Zangani C, Catalani V, Vento A, Pettorruso M, Martinotti G, di Giannantonio M, Guirguis A.
Exp Neurol. 2021 Feb 8;113638. doi: 10.1016/j.expneurol.2021.113638.

Opioid painkillers' dependence in a sample of elderly medical inpatients.
Chiappini S, Schifano F, Martinotti G, Strasser J, Bonnet U, Scherbaum N.
Psychogeriatrics 2021; 21: 265–271. doi: 10.1111/psyg.12658.

The benzydamine experience: a systematic review of benzydamine abuse.
Chiappini S, Miuli A, Mosca A, Pettorruso M, Guirguis A, Corkery JM, Martinotti G, Di Giannantonio M, Schifano F.
Curr. Neuropharmacol. 2021 Oct 18;19(10):1728-1737. doi: 10.2174/1570159X19666210113151136.

Understanding the use of prescription and OTC drugs in obtaining highs and the pharmacist role in preventing abuse.
Chiappini S, Guirguis A, Corkery J, Schifano F.
TOP ONE RESEARCH ARTICLE 2020
The Pharmaceutical Journal Vol.305, No 7943, online
(https://www.pharmaceutical-journal.com/research/perspective-article/misuse-of-prescription-and-over-the-counter-drugs-to-obtain-illicit-highs-how-pharmacists-can-prevent-abuse/20208538.article?firstPass=false) doi: 10.1211/PJ.2020.20208538.

What about 'pharming'? Issues regarding the misuse/abuse of prescription and over-the-counter drugs.
Chiappini S, Schifano F.
Brain Sci. 2020 Oct; 10(10): 736. doi: 10.3390/brainsci10100736.

Beyond the PURPLE DRANK. Study of promethazine abuse according to the European Medicines Agency (EMA) Adverse Drug Reactions (ADR) reports.
Chiappini S, Schifano F, Corkery JM, Guirguis A.
J Psychopharmacology, 2021 Jun;35(6):681-692. doi: 10.1177/0269881120959615.

Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports.
Schifano N, **Chiappini S,** Castiglione F, Salonia A, Schifano F.
Low Urin Tract Symptoms. 2021 Apr;13(2):230-237. doi: 10.1111/luts.12355.

COVID-19: The hidden impact on mental health and drug addiction.
Chiappini S, Guirguis A, John A, Corkery JM, Schifano F.
Front Psychiatry. 2020; 11: 767. Doi:10.3389/fpsyt.2020.00767.

'Z-trip'? A comprehensive overview and and a case-series of Zolpidem misuse.

Orsolini L, **Chiappini S,** Grandinetti P, Bruschi A, Testa R, Provenzano A, De Berardis D.
Clin Psychopharmacol Neurosci. 2021 May 31;19(2):367-387. doi: 10.9758/cpn.2021.19.2.367.

How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy
Orsolini L, Chiappini S, De Berardis D, Papanti DG, Tomasetti C, Fornaro M, Vellante F, Latini R, Volpe U.
Hum Psychopharmacol Clin Exp. 2020;e2728.

Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database.
Chiappini S, Schifano F, Corkery JM, Guirguis A.
Brain Sci. 2020, 10(2), 105. doi:10.3390/brainsci10020105.

New/Designer Benzodiazepines': an analysis of the literature and psychonauts' trip reports".
Orsolini L, Papanti D, Vento A, Chiappini S, Guirguis A, Corkery JM, Schifano F.
Curr Neuropharmacol. 2020 Jan 10. doi: 10.2174/1570159X18666200110121333.

The bridge between classical and 'synthetic'/chemical psychoses: towards a clinical, psychopathological and therapeutic perspective.
Orsolini L, **Chiappini S,** Papanti D, De Berardis D, Corkery JM, Schifano F.
Front. Psychiatry. 2019 Nov 20;10:851. Doi: 10.3389/fpsyt.2019.00851.

The role of novel psychoactive substances (NPS) in mental health care of young people; a systematic review.
Orsolini **L, Chiappini S,** Corkery JM, Guirguis A, Papanti D, Schifano F.
Expert reviews of neurotherapeutics. 2019 Sep 24:1-12. doi: 10.1080/14737175.2019.1666712.

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review.
Orsolini L, **Chiappini S,** Volpe U, De Berardis D, Latini R, Papanti GD, Corkery JM.
Medicina. 2019, 55, 525; doi:10.3390/medicina55090525.

Cannabidiol (CBD) Use in Psychiatric Disorders: a Systematic Review.
Bonaccorso S, Ricciardi A, Zangani C, **Chiappini S,** Schifano F.
Neurotoxicology. 2019 Sep;74:282-298. doi: 10.1016/j.neuro.2019.08.002.

New/emerging psychoactive substances and associated psychopathological consequences.
Schifano F, Napoletano F, **Chiappini S,** Guirguis A, Corkery JM, Bonaccorso S, Ricciardi A, Scherbaum N, Vento A.
Psychological Medicine 2019; 1–13. doi:10.1017/S0033291719001727.

New psychoactive substances (NPS), psychedelic experiences, and dissociation; clinical and clinical pharmacological issues.
Schifano F, Napoletano F, **Chiappini S,** Orsolini L, Guirguis A, Corkery JM, Bonaccorso S, Ricciardi A, Scherbaum N, Vento A.
Current Addiction Reports (2019) 6:140–152. doi: 10.1007/s40429-019-00249-z.

Pregabalin: a range of misuse-related unanswered questions.
Schifano F, **Chiappini S.**
CNS Neurosci Ther. 2019 May;25(5):659-660.oi: 10.1111/cns.13115.

An insight into Z-drugs abuse and dependence: an examination of reports to the European Medicines Agency (EMA) database of suspected Adverse Drug Reactions (ADR).
Schifano F, **Chiappini S,** Corkery JM, Guirguis A.
Int J Neuropsychopharmacol. 2019 Apr 1;22(4):270-277. doi: 10.1093/ijnp/pyz007.

Assessing The 2004-2018 Fentanyl Misusing Issues Reported To An International Range Of Adverse Reporting Systems
Chiappini S, Schifano F, Guirguis A, Corkery JM.
Front. Pharmacol. 2019; 10:46. doi: 10.3389/fphar.2019.00046.

Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports.
Schifano F, **Chiappini S.**
PLoS ONE 2018; 13(10): e0204443. doi: 10.1371/journal.pone.0204443.

Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review
Schifano F, **Chiappini S**, Corkery J, Guirguis A.
EDITOR'S CHOICE ARTICLE
Brain Sci. 2018, 8(4), 73. doi:10.3390/brainsci8040073.

There is a potential of misuse for venlafaxine and bupropion?
Schifano F, **Chiappini S.**
Front. Pharmacol. 2018; 9:239. doi: 10.3389/fphar.2018.0023921.

β-2 agonists as misusing Drugs? Assessment of both Clenbuterol- and Salbutamol-related European Medicines Agency (EMA) Pharmacovigilance Database Reports.
Milano G, **Chiappini S,** Mattioli F, Martelli A, Schifano F.
Basic Clin Pharmacol Toxicol. 2018 Mar 2. doi: 10.1111/bcpt.12991.

Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions' database.
Chiappini S, Schifano F.
J Clin Psychopharmacol. 2018 Feb;38(1):72-79. doi: 10.1097/JCP.0000000000000814.

A decade of gabapentinoid misuse: an analysis of the European Medicines Agency's 'suspected adverse drug reactions' database. Assessment of gabapentinoid misuse/dependence as reported to the EMA.
Chiappini S, Schifano F.
CNS drugs 2016, 30,5: 1-8. doi: 10.1007/s40263-016-0359-y.

Compulsiveness dimension in a case of Pathological Gambling.
Chiappini S, Testa R, Di Paolo M, Leone B, Maisto F, Pascucci M, Grandinetti P, Polidori F, Conte G.
European Psychiatry 33S (2016) S353-354.

Deaths of individuals aged 16–24 years in the UK after using mephedrone.
Loi B, Corkery JM, Claridge H, Goodair C, **Chiappini S,** Gimeno Clemente C, Schifano F.
Hum Psychopharmacol Clin Exp 2015; 30(4):225-232.

Methoxetamine-related deaths in the UK: an overview .
Chiappini S, Claridge H, Corkery JM, Goodair C, Loi B, Schifano F.
Hum Psychopharmacol Clin Exp 2015; 30: 244–248

Age in Pathological Gambling: Correlations with Personality and Psychiatric Comorbidity.
Pascucci M, Pettorruso M, Villella C, Righino E, Ciciarelli C, **Chiappini S,** Di Cesare A, Testa R, Di Paolo M, Janiri L, Conte G.
European Psychiatry 2015, 30, Supplement 1, 28–31: 499.

Online Gambling, Impulsivity and Personality Traits: an Italian Sample.
Pascucci M, **Chiappini S**, Villella C, Righino E, Pettorruso M, Ciciarelli C, Di Cesare A, Testa R, Di Paolo M, Janiri L, Conte G.
European Psychiatry 2015, 30, Supplement 1, 28–31: 1086.

Validation of a diagnostic questionnaire based on DSM-IV criteria for gambling.
Sabetta L, Di Paolo M, Testa R, **Chiappini S,** Pettorruso M, Di Cesare A, Villella C, Conte GL.

European Psychiatry 2013, 28, Supplement 1, 1.

Glutamatergic strategies in the treatment of pathological gambling: a pilot study.
Pettorruso M, Conte G, Righino E, Di Cesare A, **Chiappini S,** Testa R, Janiri L.
European Psychiatry 2013, 28, Supplement 1, 1.

Behavioural changes in cocaine dependent patients after group-therapy
Di Paolo M, Chiappini S, Testa R, Pettorruso M, Di Cesare A, Sabetta L, Conte GL.
European Psychiatry 2013, 28, Supplement 1, 1.

Relationship between impulsivity, mood disorders and personality traits in a sample of pathological gamblers.
Righino E, Pascucci M, Pettorruso M, Ciciarelli C, Di Cesare A, **Chiappini S**, Giallonardo V, Villella C, Conte GL.
European Psychiatry 2012, 27, Supplement 1, 1.

Evaluation of an italian sample of gamblers with dannon ainhold gambling scale: preliminary study
Pascucci M, Pettorruso M, Righino E, Villella C, Ciciarelli C, Di Cesare A, **Chiappini S**, Testa R, Conte GL, Dannon PN.
European Psychiatry 2012, 27, Supplement 1, 1.

Psychosocial risk factors for postpartum depression: a descriptive sample of pregnants.
Chiappini S, D'Oria L, Righino E, Bruschi A, Di Nardo D, Oliva G, Janiri L.
European Psychiatry 2012, 27, Supplement 1, 1

Psychopathologic aspects of obesity: psychodiagnostic evaluations of bariatric surgery applicants.
Chiappini S, Righino E, Ciciarelli C, Pettorruso M, Conte GL.
European Psychiatry 2011, 26, 714.

Publications on non-peer-reviewed journals

Semaglutide for Craving Reduction in a Cocaine Dependent Patient: A Case Report. Sileoni, A. M., Turco, E. T., Semeraro, F., Cavallotto, C., Mosca, A., **Chiappini**, S., & Martinotti, G. (2025). Clinical Neuropsychopharmacology and Addiction, 1(1), 3. https://www.sciltp.com/journals/cna/articles/2506000727

[Trazodone Contramid® nel paziente depresso con abuso di alcol] Article in Italian.
Dattoli L, Chiappini S.
Esperienze cliniche in Psichiatria. Suppl. 2/2023, pag.14-15.

[Lurasidone as a new therapeutic approach for the treatment of double diagnoses: a case report] Article in Italian. Chiappini S, Dattoli L, Martinotti G.
Evidence-based Psychiatric Care 2023;9(1 Suppl 1):7-8; https://doi.org/10.36180/2421-4469-2023-S4

Brexpiprazole as an augmentation agent to a selective serotonin reuptake inhibitor (SSRI) in the treatment of a case of somatization disorder
Chiappini S, Mosca A, Martinotti G, Di Carlo F, Miuli A, Dattoli L, Pettorruso M, Di Giannantonio M.
Emerg Trends Drugs Addict Health 2022: 100031

Special M related fatalities in the UK.
Chiappini S, Claridge H, Corkery J, Goodair C, Loi B, Schifano F.
Research and Advances in Psychiatry 2014;1(Suppl. 1):38.

Methoxetamine: An Analogue of Ketamine.
Chiappini S, Claridge H, Corkery J, Gimeno Clemente C, Goodair C, Loi B, Schifano F.

Current Drug Abuse Reviews, 2013, 6: 84-5.

Fatalities Associated with Mephedrone in Combination with Other Stimulant Drugs in Young People Aged 16-24 Years.
Loi B, Chiappini S, Claridge H, Corkery J, Gimeno Clemente C, Goodair C, Schifano F.
Current Drug Abuse Reviews, 2013, 6: 292-3.

The Unregulated Psychoactive Compound: 'Benzo Fury'.
Gimeno Clemente C, Chiappini S, Claridge H, Corkery J, Goodair C, Loi B, Schifano F.
Current Drug Abuse Reviews, 2013, 6: 286.

Before the treatment of Gambling: how personality characteristics influence access to our service?
Conte GL, Ciciarelli C, Di Cesare A, Chiappini S, Testa R, Martinotti G, Janiri L.
Italian Journal of Addiction, 2012, 2, 3-4.

A doubtful case of dyskinesia: a psychogenic movement disorder, a consequence of a psychofarmacological therapy, or both?
Testa R, Chiappini S, Okulska J, Di Cesare A, Pettoruso M, Conte G.
L'altro-2012, n.2 Maggio-Agosto.

Psychometric tests and risk factors for screening of mood disorders in pregnancy and post-partum: a preliminary study.
D'oria L, Leggieri C, Chiappini S, Janiri L, Oliva G.
Italian Journal of Gynaecology and Obstetrics, 2012 9-17 (9).

A Rorschach test study on the personality characteristics of a sample of pathological gamblers compared to healthy controls.
Villella C, Di Gioia A, Martinotti G, Pomponi M, Righino E, Ciciarelli C, Pettorruso M, Di Cesare A, Pascucci M, Chiappini S, Conte G.
Dipendenze patologiche 2011; 1:19-22.

Chapters

[Nuove tipologie di sostanze Psicoattive]
Martinotti G, **Chiappini S.**
In *Psicologia e psicopatologia delle nuove dipendenze* - Ornella Corazza, Gianluca Esposito. Zanichelli, 2025. ISBN: 9788808699398

Synthetic cannabinoids , the largest and most diverse group of novel psychoactive substances
Duccio P. Papanti;Laura Orsolini;John M. Corkery;Stefania Chiappini;Amira Guirguis;Alessandro Vento;Fabrizio Schifano
https://hdl.handle.net/11566/338112
in CANNABINOIDS (Autori: COLIZZI MARCO; DE GREGORIO DANILO; QUATTRONE DIEGO; Editore: MINERVA MEDICA; Anno: 2024; ISBN: 9788855322676)

Novel psychoactive substances (NPAs): a new pandemic in mental health field?
Chiappini S, Cavallotto C, Piro T, Semeraro F, Martinotti G,
In Social Determinants of Mental Health edited by Fiorillo and De Giorgi. Springer (2024)

[Capitolo 16. Disturbi Da uso Di alcol e Sostanze] (IT)
Autori: Luigi Janiri, Giovanni Martinotti, Gino Pozzi, Luisa De Risio, Stefania Chiappini
In TRATTATO di PSICOFARMACOTERAPIA CLINICA. Giovanni Fioriti Editore (2024).

[PARTE 2 NUOVE SOSTANZE PSICOATTIVE. 2.2 Tipologie – stimolanti, psichedelici, cannabinoidi, oppioidi, altre principali tipologie] (IT)
Autori: Giovanni Martinotti, Stefania Chiappini
In PSICOLOGIA E PSICOPATOLOGIA DELLE NUOVE DIPENDENZE A CURA DI CORAZZA, ESPOSITO – ZANICHELLI (2024)

Papanti P GD, Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, SCHIFANO F. Synthetic Cannabinoids, the largest and most diverse group of novel psychoactive substances (NPS). In "Cannabinoids" edited by Dr. Marco Colizzi, Dr. Danilo De Gregorio and Dr. Diego Quattrone. Edizioni Minerva Medica S.p.A.; in press

[Le nuove sostanze psicoattive] (IT)
Martinotti G, Chiappini S, Santacroce R, Cinosi E, Schifano F, di Giannantonio M

In Manuale di Psichiatria edited by Siracusano A. Il Pensiero Scientifico Editore (2022).

NPS Stimulants
Schifano F, Corkery JM, Catalani V, Chiappini S, Arillotta D, Vento A, Scherbaum N, Guirguis A
In New psychoactive substances. Challenges, consequences and treatment approaches edited by Kristina Adorjan, Sharon Walsh and Thomas G. Schulze. Oxford University Press (2021).

Psychobiological; medical; and psychiatric implications of new/novel psychoactive substance (NPS) use.
Schifano F, Chiappini S, Catalani V, Napoletano F, Arillotta D, Zangani C, Guirguis A, Vento AE, Bonaccorso S, Corkery JM.
Chapter 11 (pp. 213-233) in Murphy, P. (ed.). Psychobiological Issues in Substance Use and Misuse. Routledge.
https://books.google.co.uk/books?hl=en&lr=&id=-mQPEAAAQBAJ&oi=fnd&pg=PT212&ots=9x3DvDxNag&sig=jFMMvfi1BAHKIMZtjMGqjSJDPEE#v=onepage&q&f=false
ISBN hardback: 978-0-367-27360-6; ISBN paperback: 978-0-367-27361-3; ISBN e-book: 978-0-429-29634-5 (2021).

[Nuove frontiere nell'abuso di sostanze, psiconauti e internet] (IT)
Zangani C, Chiappini S, Napoletano F, Orsolini L, Schifano F.
In Prevenzione, giovani e… come investire nella formazione scolastica per la salute, Modonutti GB. Edizioni Goliardiche (2020).

[NUOVE SOSTANZE PSICOATTIVE] (IT)
Santacroce R, Martinotti G, Chiappini S, Schifano F.
In Compendio di Psicopatologia, edited by Martinotti G, Di Giannantonio M, Janiri L. Ed.fila 37 (2019)..

Substance-Use Disorders and Violence
Schifano F, Zangani C, Chiappini S, Guirguis A, Bonaccorso S, Corkery J.
Series Title: Comprehensive Approach to Psychiatry In Violence and Mental Disorders (2019).

[Cannabis: evidenze epidemiologiche, cliniche e terapeutiche] (IT)
Chiappini S, Schifano F.
In UNOSUQUATTRO. Diffusione e significati del consumo di cannabinoidi tra gli adolescenti: una questione educativa edited by Iori V, Gianotti F. Franco Angeli Editore (2019).

Acknowledgements

External collaborator for the contribution on carisoprodol in the WHO Expert Committee on Drug Dependence Forty-seventh report (2025)
https://www.who.int/publications/i/item/9789240096745

EMCDDA. Mini guide on the non-medical use of medicines: health and social responses 2021.
https://www.emcdda.europa.eu/publications/mini-guides/non-medical-use-of-medicines-health-and-social-responses_en

Drug-related deaths in the UK Annual Report 2013
Ghodse H, Corkery J, Claridge H, Goodair C, Schifano F.

WHO Expert Committe on Drug Dependence -Forty-sixth report
2024

Poster presentations

SIPS 2025, Firenze (IT)
NOVEL PSYCHOACTIVE SUBSTANCES (NPS) AS A RISK FACTOR FOR PSYCHOSIS: A SYSTEMATIC REVIEW OF THE LITERATURE
Alessio Mosca, Stefania Chiappini, Gianluca Mancusi, Clara Cavallotto, Andrea Miuli, Arianna Pasino, Maria Chiara Santovito, Carlotta Marrangone, Maria Chiara Vicinelli, Mauro Pettorruso, Giovanni Martinotti

SIPS 2025, Firenze (IT)
SOLASTALGIA ED ECO-ANSIA: UNA SURVEY SUGLI EFFETTI DEL CAMBIAMENTO CLIMATICO SULLA SALUTE MENTALE

Alessio Mosca, Stefania Chiappini, Giulia Giovannetti, Giulia Stefanelli, Arianna Pasino, Clara Cavallotto, Carlotta Marrangone, Mauro Pettorruso, Giovanni Martinotti

SIPS 2025, Firenze (IT)
Factors influencing the onset and severity of depressive symptoms: a survey-based study in Italy
Stefania Chiappini, Cavallotto; Alessio Mosca; Mariapia di Paolo; Valerio Ricci, Mauro Pettorruso,, Giovanni Martinotti

SIPS 2024, Lecce (IT)
Transcranial Direct Current Stimulation (tDCS) per il trattamento in acuto di pazienti affetti da Disturbo da Uso di Alcol.
Stefania Chiappini, Clara Cavallotto, Andrea Miuli, Francesco di Carlo, Gianluca Mancusi, Giulia Cortini, Alessio Mosca, Francesco Semeraro, Mariapia Di Paolo, Carlotta Marrangone, Giacomo d'Andrea, Mauro Pettorruso, Giovanni Martinotti

SIP 2024, Verona (IT).
LURASIDONE BENEFICIAL EFFECTS IN SCHIZOPHRENIC PATIENTS WITH COMORBID ALCOHOL AND SUBSTANCE USE DISORDER: A PROSPECTIVE, MULTICENTRIC, REAL-WORLD INVESTIGATION **(PRIZE BEST POSTER)**
Chiappini S., Cavallotto C., Dattoli L., Mosca A., Piro T., Marrangone C., Semeraro F., Di Paolo M.P. , Di Carlo F., D'Andrea G., Pepe M., Di Nicola M., Ricci V., Petttorruso M, Martinotti G.

CINP 2024, May 2024, TOKYO (JAPAN)
PHARMACOVIGILANCE SIGNALS OF SEMAGLUTIDE AND OTHER GLP-1 RECEPTOR AGONISTS: AN ANALYSIS OF THE FOOD AND DRUG ADMINISTRATION (FDA) ADVERSE EVENTS REPORTING SYSTEM (FAERS) DATASET
ChiappiniS., D'Andrea G., Cavallotto C., Mosca A., Di Carlo F., Petttorruso M, Martinotti G, Schifano F.

Percorsi 2023
Gestione dei pazienti con depressione resistente al trattamento in comorbilità con il disturbo da uso di sostanze: sicurezza ed efficacia dell'esketamina in un sottocampione di pazienti dello studio REAL-ESK.
ChiappiniS; d'Andrea G; Cavallotto C; Mosca A; Dattoli L; Sensi S; Pettorruso M; Martinotti G; REAL-ESK study group

SIP 2022
The opioid epidemic over the past 10 years: pharmacovigilance signals from the European Medicines Agency (EMA) and the FDA Adverse Event Reporting System (FAERS)
Chiappini S, Mosca A, Guirguis A, Corkery JM, Di Giannantonio M, Martinotti G, Schifano F.

SIP 2022
A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): An Analysis of Pharmacovigilance Databases
Chiappini S, Guirguis A, Corkery JM, Martinotti G, Schifano F.

Life and Medical Science Conference- University of Hertfordshire, Hatfield (UK)
A Focus On Abuse/Misuse And Withdrawal Issues With Selective Serotonin Reuptake Inhibitors (Ssris): An Analysis Of Pharmacovigilance Databases
Chiappini S, Guirguis A, Corkery JM, Schifano F.

Life and Medical Science Conference- University of Hertfordshire, Hatfield (UK)
Alprazolam-Related Deaths in Scotland, 2004-2020
Corkery, JM, Guirguis A, Chiappini S, Martinotti G, Schifano F.

Life and Medical Science Conference- University of Hertfordshire, Hatfield (UK)
The benzydamine experience: an analysis of benzydamine related data from the European Monitoring Agency (EMA) Adverse Drug Reactions (ADR) database.
Chiappini S, Miuli A, Mosca A, Guirguis A, Corkery JM, Martinotti G, Schifano F.

RPS Science & Research Summit-London (UK)
The misuse of prescription drugs in the digital era: pros and cons.
Chiappini S, Guirguis A, Corkery JM, Schifano F.

VII New Psychoactive Substances conference- online ed.

BEYOND THE PURPLE DRANK. STUDY OF PROMETHAZINE ABUSE ACCORDING TO THE EUDRAVIGIALNCE DATASET.
Chiappini S, Schifano F, Corkery JM, Guirguis A.

Royal Pharmacology Society Annual Conference, London (UK)
ARE Z-DRUGS SAFE? STUDY OF THEIR MISUSE, ABUSE AND DEPENDENCE ACCORDING TO THE EUROPEAN MEDICINES AGENCY (EMA) PHARMACOVIGILANCE DATABASE.
Chiappini S, Guirguis A, Corkery J, Schifano F.

NPS conference- Maastricht (NL)
Loperamide diversion and abuse: assessment of its non-medical use through the analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports.
Chiappini S, Corkery, JM, Guirguis, A, Schifano F.

Life and Medical School Research Conference, University of Hertfordshire, Hatfield, UK.
The uncontrollable rise of opioids. Study of the European situation from the EudraVigilance adverse drug reactions database of fentanyl abuse/misuse/ dependence cases.
Chiappini S, Schifano F, Corkery JM, Guirguis A.

School of Health and Social Work Annual Research Conference 2018- University of Hertfordshire, Hatfield, UK
Prescription drug diversion and misuse. Assessment of the non-medical use of a range of molecules through pharmacovigilance databases.
Chiappini S, Corkery, JM, Guirguis, A, Schifano F.

Life and Medical School Research Conference, University of Hertfordshire, Hatfield, UK
Analysis of European Monitoring Agency (EMA) EudraVigilance Adverse Drug Reactions database; a pharmacovigilance approach to the study of prescription drug misuse in the context of the Novel Psychoactive Substances (NPS) phenomenon.
Chiappini S, Schifano F, Corkery JM, Guirguis, A.

IV National Meeting of Young Psychiatrist-Rome (IT)
Hedonic tone dysfunctions and Dopamine Transporter Availability in Gambling Disorder: Preliminary data from a 123I-FP-CIT SPECT study
Pettorruso M, Di Nicola M, Chiappini S, Conte E, Romano B, Di Giuda D, Tascone E, Curcio E, Cocciolillo F, Giordano A, Conte G, Janiri L

European Psychiatric Association (EPA) Congress, Madrid (Spain)
Compulsiveness dimension in a case of Pathological Gambling
Chiappini S, Testa R, Di Paolo M, Leone B, Maisto F, Pascucci M, Grandinetti P, Polidori F, Conte G.

European Psychiatric Association (EPA) Congress, Vien (Austria)
Age in Gambling: correlations with personality and psychiatric comorbidity.
M. Pascucci, M. Pettorruso, C. Villella, E. Righino, C. Ciciarelli, S. Chiappini, A. Di Cesare, R. Testa, L. Janiri, G. Conte

European Psychiatric Association (EPA) Congress, Vien (Austria)
Online gambling, impulsivity and personality traits: an Italian Sample.
Pascucci M, Chiappini S, Villella C, Righino E, Pettorruso M, Ciciarelli C, Di Cesare A, Testa R, Janiri L, Conte G.

17th Congress of the European Society for Sexual Medicine, Copenaghen (Denmark)
Hyper sexuality and compulsive behaviors triggered by dopaminergic therapies in a case of Parkinson's Disease.
(awarded to receive a Travel Grant supported by Lilly)
[Available online at:
http://www.essm.org/fileadmin/user_upload/medien/dokumente/Cases_that_Matter/04_2015/Chiappini_Case.pdf]

XVI World congress of Psychiatry, Madrid (Spain)

Behavioural Addictions In Adolescence: Findings From An Italian Survey
Di Nicola M, Chiappini S, Grandinetti P, De Vita O, Pettorruso M, Conte G, Janiri L.

XVI World congress of Psychiatry, Madrid (Spain)
Validation of a new Gambling Questionnaire based on DSM-IV-TR Criteria
Pascucci M, Villella C, De Waure C, Righino E, Ciciarelli C, Pettorruso M, Di Cesare A, Chiappini S, Janiri L, Bria P, Conte G.

Third Novel Psychoactive Substances Conference, Rome (Italy)
'Special M' related fatalities in the UK **(PRIZE BEST POSTER)**
Chiappini S, Claridge H, Corkery J, Goodair C, Loi B, Schifano F.

Third Novel Psychoactive Substances Conference, Rome (Italy)
Gabapentinoids' misuse issues
Schifano F, Chiappini S

American Psychiatric Association's 167th Annual Meeting, New York (USA)
A multidisciplinary approach for addiction treatment in an Italian day hospital service: a therapy model and its goals.
Chiappini S, Testa R, Di Paolo M, Grandinetti P, Hatzigiakoumis DS, Conte G

American Psychiatric Association's 167th Annual Meeting, New York (USA)
Pregabalin treatment in pathological gambling: a preliminary study
Testa R, Pettorruso M, Di Nicola M, Martinotti G, Di Paolo M, Di Cesare A, Chiappini S, Conte G, Janiri L

Society for Study of Addiction Annual Symposium, York (UK)
Methoxetamine: an analogue of Ketamine.
Chiappini S, Claridge H, Corkery J, Gimeno Clemente C, Goodair C, Loi B, Schifano F.

XI Congresso Società Italiana di Psichiatria Biologica, Naples (Italy)
Utilizzo del pregabalin nel trattamento del gioco d'azzardo patologico: dati preliminari
Pettorruso M, Di Nicola M, Martinotti G, Sabetta L, Di Cesare A, Chiappini S, Testa R, Conte G, Janiri L.

Second International Conference on Novel Psychoactive substances, Swansea (UK)
Methoxetamine: an analogue of Ketamine
Chiappini S, Claridge H, Corkery J, Gimeno Clemente C, Goodair C, Loi B, Schifano F

Second International Conference on Novel Psychoactive substances, Swansea (UK)
The unregulated psychoactive compound 'Benzo Fury'
Gimeno Clemente C, Chiappini S, Claridge H, Corkery J, Goodair C, Loi B, Schifano F

Second International Conference on Novel Psychoactive substances, Swansea (UK)
Fatalities associated with Mephedrone in combination with other stimulant drugs in young people aged 16-24 years
Loi B, Chiappini S, Claridge H, Corkery J, Gimeno Clemente C, Goodair C, Schifano F

10th International Training Seminar in CHILD AND ADOLESCENT PSYCHIATRY. Planning the future: research and Evidence Based Practice (Bocca di Magra, SP, Italy)
Loi B, Chiappini S, Claridge H, Corkery J, Gimeno Clemente C,Goodair C, Schifano F

European Psychiatric Association Congress, Nice (France)
Behavioural changes in cocaine dependent patients after group-therapy
Di Paolo M, Chiappini S, Testa R, Pettorruso M, Di Cesare A, Sabetta L, Conte G

European Psychiatric Association Congress, Nice (France)
Validation of a diagnostic questionnaire based on DSM-IV criteria for Gambling
Sabetta L., Di Paolo M., Testa R., Chiappini S., Pettorruso M., Di Cesare A., Villella C., Conte G.

European Psychiatric Association Congress, Prague (Czech Republic)
Evaluation of an Italian sample of gamblers with Dannon Ainhold gambling scale: a preliminary study.
Pascucci M, Pettorruso M, Righino E, Villella C, Ciciarelli C, Di Cesare A, Chiappini S, Testa R, Conte G, Dannon PN

European Psychiatric Association Congress, Prague (Czech Republic)
Relationship between impulsivity, mood disorders and personality traits in a sample of pathological gamblers
Righino E, Pascucci M, Pettorruso M, Ciciarelli C, Di Cesare A, Chiappini S, Giallonardo V, Villella C, Conte G.

European Psychiatric Association Congress, Prague (Czech Republic)
Psychosocial risk factors for postpartum depression: a descriptive sample of pregnants
Chiappini S, D'Oria L, Righino E, Bruschi A, Di Nardo F, Oliva G, Janiri L

Global Addiction, Lisbon (Portugal)
Mobile phone use during adolescence: a new addiction?
Ciciarelli C, Villella C, Righino E, Di Cesare A, Pettorruso M, Chiappini S, Pascucci M, Martinotti G, Di Nicola M, Janiri L, Conte G

Global Addiction, Lisbon (Portugal)
Addiction: a therapeutic model for the restructuring of identity
Chiappini S, Pettorruso M, Pizzonia G, Conte G

European Psychiatric Association Congress, Vienna (Austria)
Psychopathologic aspects of obesity: psychodiagnostic evaluations of bariatric surgery applicants
Chiappini S, Ciciarelli C, Righino E, Pettorruso M, Di Cesare A, Conte GL

Oral presentations

October 2024
Vitamina D e malattia psichiatrica: uno studio retrospettivo sulla relazione tra il dosaggio di vitamina D e disturbi dello spettro bipolare
2° Forum Nazionale ATNPN - Accademia di Terapia Naturale in Psichiatria e Neurologia - Milano, 17-18 ottobre 2024

November 2023
X International Conference on NPS (Abu Dhabi)
Understanding the opioid epidemic through pharmacovigilance signals: an analysis of pharmacovigilance datasets collecting Adverse Drug Reactions (ADRs) reported to Eudravigilance (EV) and the FDA) Adverse Events Reporting System over ten years.

May 2022
RADARS® System 16th Annual Scientific Virtual Meeting: Evolving Safety of Psychoactive Drugs
Does Over-the-Counter Mean Under the Radar? Focus On Over-The-Counter Drug Abuse

November 2021
VIII International Conference on NPS - Washington (US)
FOCUS ON OVER-THE-COUNTER DRUG ABUSE: A SYSTEMATIC REVIEW ON THE DIVERSION OF ANTIHISTAMINES, COUGH MEDICINES, AND DECONGESTANTS

December 2019
International Pathways of Psychiatry - Percorsi emozionali e traiettorie di sviluppo nella Psichiatria del futuro - XII° Meeting - Roma (IT)
NPS and abuse of psychotropic drugs.

April 2019
VI International Conference on NPS - Maastricht (NL)
Prescription and over-the-counter drug misuse in the context of the NPS scenario; considering the pharmacovigilance approach to evaluate the abuse and misuse of medications.

Diecember 2018
7th Young Psychiatric Network Meeting- Catania (IT)
The abuse of over-the-counter medications in the adolescents: the new phenomenon of 'pharming'.

April 2018
Convegno Unosuquattro, Reggio Emilia (IT)
Epidemiologic, neuropharmacological and clinical evidences on cannabis and new psychoactive substances.

March 2011
Leiden International Medical Student Conference, Leiden (Netherlands)
Psychopathologic aspects of obesity: psycho diagnostic evaluations of bariatric surgery applicants

Personal characteristics/ interpersonal skills

- Very good organisational skills, ability to prioritise and work under pressure and process a large volume of work
- Excellent communication skills
- Very good critical appraisal skills
- Ability to work collaboratively and build strong working relationships, service-minded
- Flexibility and problem-solving attitude
- Meticulous attention to detail

In compliance with the Italian Legislative Decree no. 196 dated 30.06.2003, I hereby authorize the recipient of this document to use and process my personal details contained in this document.



August 30th, 2025